Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Foghorn Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-97.49 Mil. Foghorn Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $255.00 Mil.
Therefore, Foghorn Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was -0.38.
The historical rank and industry rank for Foghorn Therapeutics's Equity-to-Asset or its related term are showing as below:
FHTX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -3.94 Med: 0.06 Max: 0.57
Current: -0.38
During the past 6 years, the highest Equity to Asset Ratio of Foghorn Therapeutics was 0.57. The lowest was -3.94. And the median was 0.06.
FHTX's Equity-to-Asset is ranked worse than 88.69% of 1565
companies
in the Biotechnology industry
Industry Median: 0.67
vs FHTX: -0.38
Foghorn Therapeutics Equity-to-Asset Historical Data
The historical data trend for Foghorn Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Foghorn Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Foghorn Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Equity-to-Asset falls into.
Foghorn Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Foghorn Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Foghorn Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Foghorn Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Foghorn Therapeutics (Foghorn Therapeutics) Business Description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FHTX has been successfully added to your 